Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Dec 2, 2021
- Accession no.
- 0001209191-21-067479
- Filed
- Dec 2, 2021
- Trade date
- Nov 30-Dec 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $63.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.40 to $1.53, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.92, inclusive.
Referenced by the price of 1 transaction in Table I.